Vorapaxar

(Zontivity®)

Zontivity®

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormTablet (oral: 2.08 mg)
Drug ClassProtease-activated receptor-1 (PAR-1) antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Vorapaxar (Zontivity) is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). It significantly reduces limb ischemia and revascularization events when compared to placebo.
  • Two studies were reviewed, providing information on the safety and effectiveness of vorapaxar in comparison to other drugs used for reducing thrombotic cardiovascular events.
  • Compared to aspirin, vorapaxar showed a significantly lower risk of all-cause mortality. However, these studies did not explicitly mention its bleeding risk, which is an important factor in assessing the safety profile of antithrombotic therapies.
  • Clopidogrel was noted as another effective option that reduces major adverse cardiovascular events without increasing bleeding risks. This makes it a preferred choice for patients at higher risk of bleeding.
  • Rivaroxaban combined with ASA also demonstrated significant reductions in composite cardiovascular outcomes but increased major bleeding risks, making it less favorable for individuals at high risk of bleeding.
  • The studies focused on broad groups including chronic coronary artery disease or PAD patients without detailed insights into population subtypes or specific subgroup considerations outside those at higher risk from MI or PAD.